News

Alivexis to present ModBind™ at MACNICA booth at the AI EXPO Tokyo- 28 October, 2024

Cathepsin C Inhibitor Proved Effective in the Treatment of Vasculitis～Expectations for a Novel Therapeutic Agent for ANCA-Associated Vasculitis～- 23 August, 2024

Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A- 21 June, 2024

Alivexis with Astellas Pharma Inc. to Collaborate on Novel Drug Target- 17 June, 2024

Joint Research on Novel Anti-Allergic Disease Drug Candidate Published by Alivexis, Inc. and University of Yamanashi- 11 April, 2024

Modulus Discovery, Inc. to Change Its Name to Alivexis, Inc. on March 11, 2024- 11 March, 2024

Modulus Discovery, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference- 09 January, 2024

PeptiDream and Modulus Announce Nomination of First Clinical Development Candidate from Strategic Partnership- 03 August, 2023

Modulus Discovery has been selected as a “J-Startup” company by the Ministry of Economy, Trade and Industry of Japan- 06 April, 2023

Modulus Discovery, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference- 13 December, 2022